Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
IGC Pharma ( (IGC) ) has provided an announcement.
On September 29, 2025, IGC Pharma‘s subsidiary, Holi Hemp LLC, entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The agreement involves the sale of equipment, inventory, and a facility for approximately $2.7 million, subject to adjustments. The transaction includes preferential supply rights for IGC Pharma and a 10% entitlement on net proceeds if the buyer sells the business within five years.
The most recent analyst rating on (IGC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.
Spark’s Take on IGC Stock
According to Spark, TipRanks’ AI Analyst, IGC is a Neutral.
The overall stock score is primarily impacted by the weak financial performance, which is a significant concern. Despite this, the stock shows positive technical momentum and promising corporate developments in Alzheimer’s research, which provide some optimism. However, the negative valuation metrics and lack of profitability weigh heavily on the overall score.
To see Spark’s full report on IGC stock, click here.
More about IGC Pharma
IGC Pharma, Inc. operates in the pharmaceutical industry and is involved in the development and commercialization of cannabinoid-based therapies.
Average Trading Volume: 3,078,158
Technical Sentiment Signal: Hold
Current Market Cap: $38.62M
See more insights into IGC stock on TipRanks’ Stock Analysis page.